BDRX
Biodexa Pharmaceuticals Plc
$3.03
-1.69%
$2.0M
No data for this timeframe.
Vol
Market Cap$2.0M
Cap SizeNano Cap
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases1
Recent Activity
May 14, 2026
SEC
Biodexa Pharmaceuticals filed its 6-K on May 14, 2026, announcing its Annual General Meeting (AGM) scheduled for June 17
6-K — Impact 4/10
May 14, 2026
other
Biodexa issues letter to Shareholders
<p>May 14, 2026</p>
Mar 31, 2026
SEC
Biodexa Pharmaceuticals Plc has had six registration statements declared effective by the SEC, enabling the company to p
EFFECT — Impact 7/10
Mar 23, 2026
Press
Biodexa Pharmaceuticals has partnered with Tanner Pharma Group to launch a global Early Access Program for its investiga
Impact 4/10
Price Targets
Historical data — last covering-analyst action Feb 2024. No current recommendation available.
$35.64 (Feb 2024)
Current $3.03
Low $35.64
Median $35.64
High $35.64
1 analysts
$35.64
$35.64
Analyst Ratings
3Strong Buy
3Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 8, 2024 | Ladenburg Thalmann | INITIATE | Buy |
Latest Reports
NEUTRAL
6-K
4/10
Biodexa Pharmaceuticals filed its 6-K on May 14, 2026, announcing its Annual General Meeting (AGM) scheduled for June 17
May 14, 2026
BEARISH
EFFECT
7/10
Biodexa Pharmaceuticals Plc has had six registration statements declared effective by the SEC, enabling the company to p
Mar 31, 2026
NEUTRAL
Press
4/10
Biodexa Pharmaceuticals has partnered with Tanner Pharma Group to launch a global Early Access Program for its investiga
Mar 23, 2026
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
Historical analyst distribution (last covering-analyst action Feb 2024): 86% buy across 7 analysts — 3 strong buy, 3 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2024. No current recommendation available.
$35.64 mean target (Feb 2024)
$35.64 Low
$35.64 High
| Metric | Value |
|---|---|
| Current Price | $3.03 |
| Target Low | $35.64 |
| Target Mean | $35.64 |
| Target Median | $35.64 |
| Target High | $35.64 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | 100.0% | — | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | 0.0% | — | 1↑ 0↓ | $0.0B | 0.0% | 1 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 8, 2024 | Ladenburg Thalmann | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 3 | 1 | 0 | 0 | 86% | |
| Dec 1, 2025 | 3 | 3 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
2 mentions
0 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 2, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
BDRX — 06:42 MT ~ $0.70
▲ 1
💬 0
⚡ 0.5
May 14, 2026
other
Biodexa issues letter to Shareholders
<p>May 14, 2026</p>
May 5, 2026
short_volume
Short Volume: BDRX — 59.5% short (0.9M / 1.5M)
Short: 905,991 | Exempt: 4,102 | TRF Vol: 1,522,667 | Short Ratio: 59.5% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
other
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
<p>April 2, 2026</p>
Apr 2, 2026
short_volume
Short Volume: BDRX — 55.6% short (32.7M / 58.9M)
Short: 32,745,894 | Exempt: 184,255 | TRF Vol: 58,928,323 | Short Ratio: 55.6% | Off-exchange volume (dark pool + OTC)
Mar 27, 2026
earnings
Preliminary Results for the Year Ended 31 December 2025
<p align="left">March 27, 2026</p>
Mar 23, 2026
contract
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
<p>March 23, 2026</p>
Mar 18, 2026
other
ADR Ratio Change
<p><b>March 18, 2026</b></p>
Mar 9, 2026
other
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
<p>March 9, 2026</p>